Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hologic (HOLX) and Amag Pharmaceuticals (AMAG).
Hologic (HOLX)
Needham analyst Michael Matson assigned a Buy rating to Hologic today and set a price target of $78.00. The company’s shares closed last Thursday at $66.45.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 8.4% and a 57.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $77.50.
See today’s analyst top recommended stocks >>
Amag Pharmaceuticals (AMAG)
Needham analyst Serge Belanger maintained a Hold rating on Amag Pharmaceuticals today. The company’s shares closed last Thursday at $13.60.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of -0.1% and a 39.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Amag Pharmaceuticals with a $11.21 average price target, which is a -13.6% downside from current levels. In a report released today, Piper Sandler also upgraded the stock to Hold with a $13.75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
